Skip to main content
. 2015 Mar 9;54(5):669–677. doi: 10.3109/0284186X.2014.996663

Table II.

Generalized linear mixed model estimating effects of Type D personality on the most relevant EORTC QLQ-C30 and EORTC QLQ-CR38 subscales regarding survivorship over time, mutually adjusted for sociodemographic and clinical characteristics.

  EORTC-QLQ-C30 EORTC-QLQ-CR38
  Global quality of life
Beta and 95% CI
Fatigue
Beta and 95% CI
Pain
Beta and 95% CI
Insomnia
Beta and 95% CI
Body image
Beta and 95% CI
Future perspective
Beta and 95% CI
Sexual enjoyment
Beta and 95% CI
Sex
 Female vs. male
2.0 0.8–3.1** − 3.9 − 5.5–− 2.3** − 4.9 − 6.7–− 3.1** − 10.7 − 12.9–− 8.6** 0.6 − 1.2–2.3 3.7 1.8–5.7** 11.8 8.3–15.2**
Agea 0.1 0.1–0.2** − 0.1 − 0.2–0.01* − 0.2 − 0.3–− 0.1** − 0.1 − 0.2–− 0.1* 0.3 0.2–0.3** 0.3 0.2–0.4** − 0.4 − 0.6–− 0.2**
Time since
diagnosisa
0.3 0.1–0.5** − 0.5 − 0.7–− 0.2** − 0.3 − 0.6–0.1 − 0.4 − 0.8–− 0.1* 0.6 0.3–0.9** 1.0 0.6–1.3** 0.1 − 0.4–0.7
Stage
 Stage I vs. IV
 Stage II vs. IV
 Stage III vs. IV

− 0.4
− 0.5
0.8

− 3.9–3.1
− 4.0–2.9
− 2.6–4.1

− 3.9
− 3.6
− 4.4

− 8.6–0.8
− 8.2–1.0
− 8.8–0.1

− 2.1
− 1.4
− 0.9

− 7.3–3.0
− 6.5–3.7
− 5.8–4.0

2.2
0.9
2.2

− 4.3–8.6
− 5.4–7.2
− 3.9–8.3

− 4.8
− 3.9
− 3.2

− 9.9–0.4
− 8.9–1.2
− 8.0–1.7

12.3
10.7
9.6

6.6–18.0**
5.0–16.3**
4.2–15.1**

− 4.1
− 2.4
− 4.0

− 13.5–5.4
− 11.6–6.9
− 12.9–4.9
Chemotherapy
yes vs. no
1.1 − 0.6–2.7 − 1.2 − 3.4–1.0 0.9 − 1.5–3.3 0.1 − 2.9–3.1 1.7 − 0.8–4.0 0.3 − 2.4–3.0 − 0.6 − 5.0–3.8
Comorbid conditionsa − 2.3 − 2.7–− 2.0** 2.6 2.2–3.0** 4.0 3.5–4.5** 1.9 1.3–2.5** − 0.6 − 1.1–− 0.2** − 1.8 − 2.4–− 1.3** 0.1 − 0.8–1.0
Partner
no vs. yes
0.6 − 0.7–2.0 − 1.8 − 3.6–− 0.1* − 2.7 − 4.7–− 0.6* − 4.6 − 7.1–− 2.2** − 0.7 − 2.7–1.3 0.8 − 1.4–3.1 1.6 − 2.8–6.0
Education
 High vs. Middle
 High vs. Low

0.2
0.1

− 1.1–1.5
− 1.7–1.9

0.1
− 1.1

− 1.7–1.7
− 3.4–1.3

0.6
1.1

− 1.4–2.5
− 1.5–3.8

0.6
− 0.1

− 1.8–2.9
− 3.2–3.2

1.0
2.3

− 0.8–2.8
− 0.1–4.9

0.8
1.6

− 1.3–3.0
− 1.3–4.6

− 0.1
− 3.7

− 3.4–3.3
− 8.8–1.5
Time
 T2 vs. T1
 T3 vs. T1

− 1.1
− 1.3

− 1.9–− 0.3**
− 2.2–− 0.4**

0.2
0.8

− 0.8–1.1
− 0.3– 1.8

0.7
0.7

− 0.5–1.8
− 0.6–1.9

− 0.5
0.7

− 1.8–0.7
− 0.7–2.2

1.1
0.4

0.1–2.1*
− 0.7–1.5

1.5
0.6

0.2–2.7*
− 0.8–2.0

0.4
− 1.1

− 1.8–2.5
− 2.5–2.3
Depressiona − 2.2 − 2.4–− 2.1** 2.5 2.3–2.7** 1.7 1.5–1.9** 1.6 1.3–1.9** − 1.8 − 2.0–− 1.6** − 2.2 − 2.5–2.0** − 1.5 − 2.0–− 1.1**
Type D
 NA-/SI+ vs. NA-/SI-
 NA+/SI- vs. NA-/SI-
 NA+/SI+ vs. NA-/SI-

− 0.7
− 3.5
− 2.3

− 2.3–0.8
− 5.5–− 1.6**
− 3.9–− 0.6**

0.2
5.1
1.8

− 1.9–2.3
2.5–7.7**
− 0.4–4.0

0.4
3.3
0.1

− 1.9–2.7
0.5–6.2*
− 2.3–2.6

0.1
8.0
4.3

− 2.8–3.0
4.5–11.6**
1.3–7.3**

− 1.0
− 6.2
− 4.9

− 3.3–1.3
− 9.0–− 3.3**
− 7.3–− 2.5**

− 0.5
− 11.1
− 7.5

− 3.1–2.1
− 14.2–− 7.9**
− 10.2–− 4.8**

− 4.7
3.9
− 6.4

− 9.0–− 0.5*
− 1.5–9.2
− 10.9–− 2.0**

Only those who completed two or more questionnaires were included in the analyses.

A selection of the EORTC QLQ-C30 and EORTC QLQ-CR38 subscales that are most relevant with respect to survivorship are included in this figure [21].

aContinuous variables are grand-mean centered; *p < 0.05; **p < 0.01.